Human antibodies that bind human IL-12, their use and methods for producing, pharmaceutical composition containing it, nucleic acid and recombinant vector, which they coded, and host cell
SALFELD JOCHEN G.,ROGUSKA MICHAEL,PASKIND MICHAEL,BANERJEE SUBHASHIS,TRACEY DANIEL E.,WHITE MICHAEL,KAYMAKCALAN ZEHRA,LABKOVSKY BORIS,SAKORAFAS PAUL,FRIEDRICH STUART,MYLES ANGELA,VELDMAN GEERTRUIDA M.
申请号：
SK13672001
公开号：
SK288082B6
申请日:
2000.03.24
申请国别(地区):
SK
年份:
2013
代理人:
摘要：
Human antibodies, preferably recombinant human antibodies that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Human antibodies, preferably recombinant human antibodies that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
